![Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]](https://static-content-prd.skipta.com/public/skipta/skipta-post/2024-07/file0L7BvG "Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]")
Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]
Source : https://pubmed.ncbi.nlm.nih.gov/38564544/
Treatment with Vyvgart is expected to cost approximately $63,200 to $94,800 per patient per course, or $298,304 to $447,456 per patient per year, depending on patient weight and assuming 4.72...
CADTH recommends reimbursing Vyvgart for adult patients with generalized myasthenia gravis (gMG) who meet specific criteria: diagnosed with class II to IV gMG, tested positive for anti-acetylcholine receptor antibodies, and have a Myasthenia Gravis Activities of Daily Living (MG-ADL) scale score of at least 5. Reimbursement conditions include...
Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa
Source : https://pubmed.ncbi.nlm.nih.gov/38336636/
The protocol for this systematic review was registered in PROSPERO: CRD42022328444.
This review highlights the importance of considering patient QoL when developing and assessing treatment and management plans for patients with gMG. However, the heterogeneity identified across studies illustrates the need for further representative and well-powered studies in large cohorts administering consistent, validated questionnaires.
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
Source : https://pubmed.ncbi.nlm.nih.gov/38760099/
The approval of monoclonal antibodies, such as ocrelizumab and ofatumumab, which target CD20, and inebilizumab, which targets CD19, for the treatment of various neuroimmunological diseases reflects progress in the understanding...
CAR T cell therapy is showing promise as a treatment for gMG, potentially offering extended disease-free survival. While initial data are encouraging, safety concerns, especially neurotoxicity, remain significant. Ongoing studies are crucial to confirm the efficacy and safety of this innovative approach, aiming to revolutionize gMG treatment...
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison
Source : https://pubmed.ncbi.nlm.nih.gov/38642198/
Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG...
Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.
Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177092/
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease with a prevalence of 150-250 cases per million individuals. Autoantibodies include long-lived antibodies against the acetylcholine receptor (AChR), mainly of the IgG1...
Early conventional immunosuppressive drugs were effective, but a series of adverse events brought great physical and psychological burdens to patients, especially those who have been using them for a long-term period. In recent years, it is not only myasthenia gravis but also many neuroimmune diseases that have gone beyond the conventional...